Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.1B
84M shares
52-week range
$3.71 – $26.95
46% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.30%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $847.0K | $0 | $0 | $0 | $0 | $0 | $0 | $105.0K |
| Gross profit | −$847.0K | $0 | $0 | $0 | $0 | $0 | $0 | −$105.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $38.6M | $38.0M | $31.8M | $29.1M | $24.5M | $16.5M | $19.4M | $33.7M |
| Operating income | −$49.2M | −$48.9M | −$43.8M | −$38.6M | −$32.6M | −$23.4M | −$27.5M | −$43.0M |
| EBITDA | −$46.1M | −$48.1M | −$5.4M | −$42.8M | −$40.9M | −$26.9M | −$62.2M | −$15.2M |
| Net income | −$46.9M | −$46.7M | −$6.0M | −$43.2M | −$41.3M | −$27.0M | −$62.3M | −$15.3M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.71 | -1.49 | -0.20 | -1.03 | -0.89 | -0.56 | -1.02 | -0.53 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $-200000 | $-0.68 | $-0.78–$-0.63 | 4 |
| 2027 | $5M | $-0.85 | $-0.98–$-0.72 | 4 |
| 2028 | $32M | $-0.75 | $-1.31–$-0.05 | 6 |
| 2029 | $84M | $-0.42 | $-0.42–$-0.42 | 4 |
Forward consensus · source: Financial Modeling Prep
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
www.corvuspharma.comNo one on the platform currently holds CRVS.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 81,310 | $1.2M |
No one on the platform has traded CRVS yet.
| $37M |
| — |
| KALVKalVista Pharmaceuticals, Inc. | $27.00 | +0.00% | $1.4B | — |
| OLMAOlema Pharmaceuticals, Inc. | $11.39 | -0.35% | $995M | — |
Source: Financial Modeling Prep · peers by sector/industry
$CRVS Big Pharma Is Buying Lately And Partnering Up with INNOVATIVE Biotech’s And CRVS Is one of them!
View on StockTwits ↗$CRVS T minus 5 days until the 250th birthday of the greatest nation on earth! God bless.
View on StockTwits ↗$CRVS Rumors on X 😂, Novartis flew to San Fran imagine......Moore to come! AD space gonna heat up after last week!
View on StockTwits ↗$CRVS This is what I keep saying! 18 months or less!
View on StockTwits ↗$CRVS Someone may have tried a pathetic attempt to prop up the price by putting in an artificially high price at close is sad and gross. The smart money ignores these anomalies . Nice try!
View on StockTwits ↗$CRVS Big Buying Volume Before the Close Of The Day! Let’s keep Up the Volume For Next Week!
View on StockTwits ↗$CRVS very happy to see CRVS picking up steam! Good luck next wee Bulls and happy weekend! Pay no attention to the Dics and Pre Dics! 🤷♂️😝😝😝😝🦎
View on StockTwits ↗$CRVS It faded all day long and then turns red. Then a few minutes before the close +3% 🤣. Great job painting the tape. I'm not impressed. I'll just say thank you for giving me the opportunity to add to my short. Prediction: Whooshing sound heard, wind kicking up.
View on StockTwits ↗$CRVS end of Q rebalancing. Good to see this one is making to MM portfolios.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.